OR-GUROBI-OPTIMIZATION
14.11.2022 15:01:59 CET | Business Wire | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the release of Gurobi Optimizer 10.0. This release provides customers with a boost to its already industry-leading speed, the ability to embed machine learning models directly into Gurobi optimization models, and new tools for model development, monitoring, and advanced diagnosis—so users can solve new types of problems, even faster than before.
Performance Improvements and Advanced Solving Techniques
The Gurobi R&D team continues to push the boundaries of performance—resulting in improvements to existing algorithms and the development of several brand-new techniques. As a result, Gurobi Optimizer 10.0 has achieved the following performance improvements since the release of Gurobi Optimizer 9.5:
Type |
Algorithm |
Overall speed-up |
On >100sec models |
LP |
Concurrent |
10% |
25% |
Primal Simplex |
3% |
10% |
|
Dual Simplex |
3% |
10% |
|
MIP |
MILP |
13% |
24% |
Convex MIQP |
57% |
2.4x* |
|
Convex MIQCP |
28% |
88%* |
|
Non-Convex MIQCP |
51% |
2.6x |
|
*MIQP and MIQCP hard model test sets are smaller than for other problem classes. |
|||
“We’ve achieved a more than 75x speedup on MILP since version 1.1. But more importantly, Gurobi 10.0 can now solve even more models easily, including some models that were, until now, intractable,” explained Dr. Tobias Achterberg, Vice President of Research and Development at Gurobi Optimization.
Gurobi 10.0 also includes the following advances in the underlying algorithmic framework:
- New network simplex algorithm – Greatly speeds up solving LPs with network structure.
- New heuristic for QUBO models, which can arise in quantum optimization – Improves Gurobi's ability to quickly find good feasible solutions for quadratic unconstrained Boolean optimization problems.
- Significant performance gains on MIPs that contain machine learning models – Results in a more than 10x improvement on certain models that contain embedded neural networks with ReLU activation functions.
- New optimization-based bound tightening (OBBT) algorithm – Greatly speeds up solving nonconvex MIQCP models.
- Reorganized concurrent LP solver – Improves performance and reduces memory footprint.
Innovative Data Science Integration
With Gurobi Machine Learning—an open-source Python project to embed trained machine learning models directly into Gurobi—data scientists can more easily tap into the power of mathematical optimization.
Specifically, Gurobi Machine Learning allows users to add a trained machine learning model as a constraint to a Gurobi model (e.g., from scikit-learn, TensorFlow/Keras, or PyTorch). Thus, users can estimate a real-world system by training a machine learning model, and then use this machine learning model as a constraint in Gurobi, in order to optimize controls on that system.
“We’re aiming to connect the world of data science with the world of optimization. With Gurobi, you can take your machine learning ‘black box’ that’s generating your predictions and plug it directly into your optimization model—enabling you to connect your forecasting with optimization,” explained Achterberg.
With this release, we're also making it more convenient to integrate gurobipy model building with pandas objects through a new, dedicated open-source package. (Available on GitHub/PyPI in Q4 2022.)
Enterprise Development and Deployment Experience
To make its solver even more accessible and easy to use, the Gurobi team has integrated new tools for model development, monitoring, and advanced diagnosis:
- Significant enhancements to the matrix-friendly API in gurobipy – All matrix-friendly modeling objects now support multiple dimensions, and dimension handling leans consistently on NumPy, including broadcasting.
- New logistic general constraint – Makes it easy to incorporate a constraint in MIP that models the logistic function.
- NuGet package for .NET – Allows .NET users to download Gurobi directly from the NuGet server.
- Memory limit parameter that allows graceful exit – Users can set a memory limit and still get the best solution and resume the optimization after the limit was hit.
- New Compute Server dashboards – The Gurobi Compute Server now includes two new dashboards, enabling users to monitor metrics over time and drill down to the actual activity to better understand the cluster usage and application behavior.
- Expanded platform support – Gurobi 10.0 includes support for Python 3.11 and Linux on ARM 64-bit.
Gurobi introduced its Web License Service (WLS) for Docker and Kubernetes container environments last year, with the release of Gurobi 9.5. With Gurobi 10.0, the team has expanded WLS to support nearly all types of containerized environments. Moreover, customers can now also obtain WLS licenses that allow them to run Gurobi in virtually all deployment scenarios, including containerized environments, virtual machines, and bare-metal machines, across Linux, macOS, and Windows.
“Our customers love our WLS and the flexibility it provides. And now they can dynamically deploy Gurobi software in even more environments,” explained Duke Perrucci, Gurobi’s Chief Operating Officer.
Additionally, starting with Gurobi 10.0, major product releases—and their subsequent minor and technical product releases—will be supported for a term of three years from the initial major product release date. For example, Gurobi version 10.0.0 (released in November 2022) and minor releases between 10.0 and 11.0 will be supported until November 2025.
“This helps create predictability for our customers, so they know exactly how long a version will be supported,” explained Dr. Sonja Mars, Director of Optimization Support at Gurobi Optimization. “We aim to deliver expert technical guidance and support for our customers—and this policy helps eliminate the guesswork. We want our customers to get the help they need, when they need it.”
Dr. Edward Rothberg, Chief Executive Officer and Co-founder of Gurobi Optimization added, “We have the absolute best minds in optimization here at Gurobi. Across every department, you’ll find people who aren’t just smart—they’re also deeply committed to our customers and to providing the best possible experience. I’m proud to be a part of this team.”
To learn more about Gurobi 10.0, please visit gurobi.com/whats-new-gurobi-10-0/.
About Gurobi Optimization
With Gurobi’s decision intelligence technology, you can make optimal business decisions in seconds. From workforce scheduling, portfolio management, and marketing optimization, to supply chain design, and everything in between, Gurobi identifies your optimal solution, out of trillions of possibilities.
As the leader in decision intelligence, Gurobi delivers easy-to-integrate, full-featured software and best-in-class support, with an industry-leading 98% customer satisfaction rating.
Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia. Over 2,500 global customers across 40+ industries run on Gurobi, including SAP, Air France, and the National Football League, as well as half of the Fortune 10 and 70% of top global tech companies. For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005243/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
